Bexion Pharmaceuticals Finalist for Cancer Support Community’s Inspiration in Cancer Research Award
COVINGTON, KY. November 8, 2016 – Bexion Pharmaceuticals was honored as a finalists for the “2016 Inspiration in Cancer Research Award” at the Cancer Support Community’s (CSC) annual Evening of Hope Gala, held on October 29, 2016.
“The Bexion team is honored to be a finalist for the CSC annual Inspiration Award,” stated Dr. Ray Takigiku, co-founder and CEO of Bexion. “This award is given to research oncologists, cancer researchers and more rarely, to organizations like ours who provide inspiration to, and make a meaningful impact in the cancer community. As we continue to progress with our clinical trials using our innovative drug candidate, BXQ-350, we hope to complement the CSC’s mission of providing support for people with cancer and their families.”
In pre-clinical animal studies, Bexion’s first-in-class biologic, BXQ-350 has been shown to induce tumor cell death in a variety of cancers. BXQ-350 is a unique formulation of a synthetically produced, human lysosomal protein. BXQ-350 is a proprietary nanovesicle formulation comprised of Saposin C (sphingolipid activator protein, or SapC) and the phospholipid dioleoylphosphatidylserine (DOPS).
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer. Bexion’s first-in-class biologic, BXQ-350, has demonstrated selective tumor targeting with the potential for clinical efficacy in a broad range of cancers. In 2013, the National Cancer Institute awarded Bexion a prestigious “Bridge Award” of $3M to support testing of BXQ-350 in the clinic. In February 2015, the FDA granted Bexion Orphan Drug status for Saposin C, the active ingredient in its proprietary drug BXQ-350, for the potential treatment of glioblastoma multiforme (GBM). In June 2015, Bexion won a Tibbett’s Award by the Small Business Administration for exemplifying the very best in innovation. In July 2016 the FDA cleared Bexion to initiate Phase I Clinical Trials.
About the Cancer Support Community
Cancer Support Community is a not-for-profit organization that provides social and emotional support for people with cancer and their families. Services are research-based, professionally-led, and free of charge, and include support groups, healthy lifestyle classes, educational programs, social activities, community resource referrals and treatment decision support.
For more information, visit bexionpharma.dev.neptuneweb.com or contact Margaret van Gilse at [email protected].
Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.